Filament Health

Filament Health Corp. (FH.NE) (“Filament”) announced today that it will be participating in three conferences throughout December 2021. These conferences include the Horizons: Perspectives on Psychedelics Conference, H.C. Wainwright 2nd…
Filament Health Corp. (FH.NE) announced today that it has entered into a co-development and exclusive licensing agreement with EntheoTech Bioscience Inc. “Our partnership with EntheoTech showcases our commitment to…
Naturally occurring psychedelic compounds such as DMT in ayahuasca, psilocybin in magic mushrooms, salvinorum A found in the salvia divinorum mint species, mescaline from peyote cacti and the scolpolamine…
Filament Health Corp. (FH.NEO) announced today that the Company has received FDA authorization to initiate the first clinical trial using naturally-sourced psychedelic substances. Additionally, this is the first approval…
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
You’d be hard pressed to find someone who hasn’t been touched by depression or anxiety. Biochemically, they’re considered co-morbid, which means they often happen at the same time and…
Welcome to Five Easy Questions with Maddy Grace where we explain the public markets and the companies that trade on them. In today’s episode, Maddy speaks with Ben Lightburn,…
Filament Health (FH.NEO) got the nod from the Financial Regulatory Authority to start trading on the OTC Pink Market in the United States under the symbol “FLHLF,” and has…
Filament Health (FH.NEO) filed their 20th patent application for their research phase programs, including three international Patent Cooperation Treaty (PCT) applications, earlier this week, according to a press release….
Filament Health (FH.NE) shipped their first batch of good manufacturing practices (GMP) certified natural psilocybin into the United States earlier this week, according to a press release.   The…